[Adult T-cell leukemia-lymphoma developed from an HTLV-1 carrier during treatment of B-cell lymphoma-associated hemophagocytic syndrome]. 2012

Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
Department of Hematology, Akita University Graduate School of Medicine, Japan.

A 63-year-old woman was admitted to our hospital with high-grade fever, liver dysfunction, and pancytopenia. Computed tomography of the whole body revealed hepatosplenomegaly but no lymphoadenopaties. Bone marrow aspiration showed infiltrations of CD20-positive large atypical B-lymphocytes with severe hemophagocytosis. Although she was a human T-cell leukemia virus type 1 carrier, the atypical lymphocyte in bone marrow had IgH rearrangement but not TCR rearrangement. From these clinical and laboratory data, the patient was diagnosed as having B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS) and treated with R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). After 4 cycles of R-CHOP, she had achieved complete remission. However, increased numbers of CD4+CD25+ flower cells were observed in peripheral blood and HTLV-1 provirus DNA was detected after 5 cycle of R-CHOP. The patient was diagnosed as adult T-cell leukemia-lymphoma (ATL) complicated by B-LAHS. Our observations suggest that continuous immunosuppressive statement for B-cell lymphoma or the chemotherapy against B-LAHS may induce the development of ATL in an HTLV-1 carrier.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014750 Vincristine An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Leurocristine,Citomid,Farmistin,Oncovin,Oncovine,Onkocristin,Vincasar,Vincasar PFS,Vincristin Bristol,Vincristin medac,Vincristine Sulfate,Vincrisul,Vintec,cellcristin,PFS, Vincasar,Sulfate, Vincristine
D015368 Human T-lymphotropic virus 1 A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC). ATLV,Adult T-Cell Leukemia-Lymphoma Virus I,HTLV-1,HTLV-I,Human T-Cell Leukemia Virus I,Leukemia Virus I, Human T-Cell,T-Cell Leukemia Virus I, Human,Adult T Cell Leukemia Lymphoma Virus I,Human T Cell Leukemia Virus I,Leukemia Lymphoma Virus I, Adult T Cell,Leukemia Virus I, Human T Cell,T Cell Leukemia Virus I, Human,Human T lymphotropic virus 1

Related Publications

Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
April 1994, Leukemia,
Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
December 2003, Reviews in clinical and experimental hematology,
Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
February 2023, Current opinion in virology,
Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
October 2007, Current hematologic malignancy reports,
Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
June 2019, Blood,
Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
September 2019, Journal of clinical and experimental hematopathology : JCEH,
Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
October 2015, The Journal of dermatology,
Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
January 2011, Acta haematologica,
Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
January 1998, Hematology (Amsterdam, Netherlands),
Takayo Nagao, and Naoto Takahashi, and Hirobumi Saitoh, and Shinsuke Noguchi, and Yong-Mei Guo, and Mitsugu Ito, and Atsushi Watanabe, and Naohito Fujishima, and Yoshihiro Kameoka, and Hiroyuki Tagawa, and Makoto Hirokawa, and Kenichi Sawada
February 1994, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!